DekaBank Deutsche Girozentrale - BIOCRYST PHARMACEUTICALS INC ownership

BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 200 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.63 and the average weighting 0.1%.

Quarter-by-quarter ownership
DekaBank Deutsche Girozentrale ownership history of BIOCRYST PHARMACEUTICALS INC
ValueSharesWeighting
Q2 2024$448
+19.5%
73,7650.0%0.00%0.0%
Q1 2024$375
-17.4%
73,7650.0%0.00%0.0%
Q4 2023$454
-14.7%
73,7650.0%0.00%0.0%
Q3 2023$532
+3.9%
73,7650.0%0.00%0.0%
Q2 2023$512
-13.8%
73,7650.0%0.00%0.0%
Q1 2023$594
-26.8%
73,7650.0%0.00%
-50.0%
Q4 2022$811
-99.9%
73,7650.0%0.00%
-33.3%
Q3 2022$895,000
+14.6%
73,7650.0%0.00%
+50.0%
Q2 2022$781,000
-35.6%
73,7650.0%0.00%
-33.3%
Q1 2022$1,213,000
+35.7%
73,765
+10.0%
0.00%
+50.0%
Q4 2021$894,000
-3.2%
67,065
+2.8%
0.00%
-33.3%
Q3 2021$924,000
-7.1%
65,2650.0%0.00%0.0%
Q2 2021$995,000
+54.7%
65,2650.0%0.00%
+50.0%
Q1 2021$643,000
-12.4%
65,265
-38.0%
0.00%
-33.3%
Q4 2020$734,000
+3.2%
105,265
-41.6%
0.00%0.0%
Q3 2020$711,000
+611.0%
180,265
+472.3%
0.00%
+200.0%
Q3 2019$100,000
-56.3%
31,500
-50.0%
0.00%0.0%
Q2 2019$229,000
-17.0%
63,000
+63.6%
0.00%
-50.0%
Q1 2019$276,000
+10.0%
38,500
+22.2%
0.00%0.0%
Q4 2018$251,000
-9.1%
31,500
-18.2%
0.00%0.0%
Q3 2018$276,000
+20.5%
38,500
-2.5%
0.00%
+100.0%
Q2 2018$229,000
+21.2%
39,5000.0%0.00%0.0%
Q1 2018$189,000
+96.9%
39,500
+12.9%
0.00%0.0%
Q1 2016$96,000
-75.3%
35,000
-5.4%
0.00%
-75.0%
Q4 2015$388,000
-6.7%
37,000
+1.4%
0.00%
-20.0%
Q3 2015$416,000
-20.5%
36,500
+4.3%
0.01%
-16.7%
Q2 2015$523,000
+72.0%
35,000
+3.9%
0.01%
+50.0%
Q1 2015$304,000
-34.9%
33,700
-12.7%
0.00%
-33.3%
Q4 2014$467,000
+13.3%
38,600
-8.3%
0.01%0.0%
Q3 2014$412,000
-19.2%
42,100
+5.2%
0.01%
-25.0%
Q2 2014$510,000
+32.1%
40,000
+9.6%
0.01%
+33.3%
Q1 2014$386,00036,5000.01%
Other shareholders
BIOCRYST PHARMACEUTICALS INC shareholders Q3 2021
NameSharesValueWeighting ↓
VHCP Management II, LLC 6,071,142$50,998,00020.86%
RTW INVESTMENTS, LP 3,458,120$29,048,0007.65%
ISZO CAPITAL MANAGEMENT LP 307,366$2,582,0004.49%
DAFNA Capital Management LLC 541,128$4,545,0003.84%
RA Capital Management 3,489,795$29,314,0003.60%
EMORY UNIVERSITY 375,348$3,153,0002.98%
Ghost Tree Capital, LLC 1,500,000$12,600,0002.35%
ACUTA CAPITAL PARTNERS, LLC 920,310$7,731,0001.83%
Avoro Capital Advisors LLC 1,603,001$13,465,0001.72%
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) 3,085,236$25,916,0001.00%
View complete list of BIOCRYST PHARMACEUTICALS INC shareholders